BioSig inks Pure EP first-in-human study deal with Texas Cardiac Arrhythmia Institute

BioSig Technologies (OTCQB: BSGM) said today that it inked a deal with Austin’s Texas Cardiac Arrhythmia Institute at St. David’s Medical Center to launch first-in-human studies using its Pure EP system. The Santa Monica, Calif.-based company’s Pure EP system is designed for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology procedures. The device is intended to reduce noise and artifacts to produce high-fidelity cardiac signals, which the company claims could increase the diagnostic values of the signals. BioSig Technologies said the first-in-human studies will be focused on validating “key value propositions” of the system and to reinforce results from pre-clinical studies that have already been released. “To better understand complex arrhythmia disease states, the ability to detect the smallest of electrical activity in various clinical situations has been a critical need for our industry. I am looking forward to the possibility that the Pure EP System will uncover these signals and advance treatment options so physicians can make more informed decisions for our patients,” study lead Dr. Andrea Natale of the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center said in a prepared statement. The launch of the studies will act as the first step in BioSig’s targeted commercial...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Cardiovascular Clinical Trials BioSig Technologies Source Type: news